TB-500 10mg

Research Overview

TB-500 is a synthetic peptide fragment derived from Thymosin Beta-4, a naturally occurring actin-binding protein. It is supplied as a lyophilized powder in an independently sealed sterile vial.

This compound is studied across cytoskeletal, vascular, and tissue research models for its role in actin sequestration, cell migration, and angiogenic signaling research. Among recovery-adjacent peptides studied in laboratory contexts, TB-500 is distinguished by its directly characterized cellular target. The fragment retains the actin-binding active region of the parent Thymosin Beta-4 molecule, including the central LKKTETQ heptapeptide responsible for many of the cellular effects documented in published research on the parent protein.

The research utility of TB-500 derives from this clarity of mechanism. A peptide with a defined biochemical target (monomeric G-actin) produces a stronger in vitro signature than peptides whose mechanisms operate primarily at the tissue level, which makes the fragment well-suited for cell-culture studies, migration assays, and other model systems where direct cellular mechanism resolution is methodologically important.

For mechanism research and model-system applications, see What Is TB-500. For comparative research on TB-500 alongside BPC-157, including the methodological basis for combination studies, see BPC-157 and TB-500 Research.

Mechanism

TB-500 represents the active region of Thymosin Beta-4 responsible for actin binding. The central LKKTETQ heptapeptide within the TB-500 sequence is the documented active site for G-actin sequestration in published research on the parent protein. Research has explored its activity in cytoskeletal organization, endothelial cell migration, and tissue research models involving angiogenesis and connective tissue dynamics.

Effects of the parent Thymosin Beta-4 on actin cytoskeletal dynamics extend to integrin-linked kinase signaling and matrix metalloproteinase expression, both documented downstream consequences of Tβ4 binding in published research. These secondary signaling effects help explain why a peptide whose primary biochemical role is actin sequestration produces such a broad range of tissue-level outcomes in published studies.

The fragment is studied for its stability and bioavailability profile in research contexts compared to the full-length parent protein. TB-500 offers laboratory researchers a shorter, more economical alternative to native Thymosin Beta-4 for in vitro and pre-clinical model work without losing the actin-binding mechanism that drives most of the documented research effects.

Product Specifications

• Compound: TB-500 (Thymosin Beta-4 fragment)
• Class: Actin-binding peptide fragment
• Purity: ≥99% (HPLC verified)
• Testing: HPLC + Mass Spectrometry
• Form: Lyophilized powder
• Container: Sterile vial
• Available Vial Size: 10mg
• Storage: Refrigerated (2 to 8 degrees Celsius)
• Documentation: Batch-specific COA available

Reconstitution and Storage

TB-500 is supplied as lyophilized powder in an independently sealed sterile vial. Reconstitution is performed by adding bacteriostatic or sterile water to the vial according to the volume protocol used in the specific research application. Reconstitution volume varies by intended working concentration; investigators selecting reconstitution methodology should reference established protocols for their experimental model.

Storage of lyophilized vials at minus 20 degrees Celsius preserves primary structural integrity and biological activity for two to three years for most well-prepared research peptides. Refrigerated storage at 2 to 8 degrees Celsius is acceptable for active inventory expected to be used within months. Once reconstituted, peptides return to aqueous-phase stability constraints. TB-500 in solution under refrigeration shows acceptable stability over several weeks based on documented research, with activity loss accelerating beyond that window.

For a detailed treatment of the freeze-drying process, storage temperatures, shelf life expectations, and quality indicators researchers use to assess lyophilized material before reconstitution, see Lyophilized Peptides: Methodology and Stability.

Quality and Verification

Every Genevium batch is independently tested by third-party laboratories. Reverse-phase HPLC confirms purity. Mass spectrometry confirms identity. Nothing ships until the compound clears a 99%+ purity threshold.

A batch-specific Certificate of Analysis is published for every order and is retrievable by batch number on the COA Lookup page. The COA documents purity by HPLC, identity by mass spectrometry, and the analytical conditions under which both were measured.

Research Applications

TB-500 is studied in research contexts where investigators require a defined-mechanism actin-binding peptide for in vitro cell migration assays, endothelial cell research, wound model systems, or comparative studies against the full-length Thymosin Beta-4 parent protein. The actin-sequestration mechanism produces a strong signature in cell-culture systems, which makes TB-500 useful in research designs where mechanism resolution at the cellular level is required.

For laboratory research using TB-500 alongside BPC-157 and GHK-Cu in a single combination formulation, the GLOW-70mg research kit is available with all three compounds supplied as independently sealed lyophilized vials.

Frequently Asked Questions

What is TB-500 and how does it differ from Thymosin Beta-4?

TB-500 is a synthetic peptide fragment that retains the actin-binding active region of the full-length Thymosin Beta-4 protein, including the central LKKTETQ heptapeptide. Thymosin Beta-4 is the 43-amino-acid endogenous protein. TB-500 is the shorter synthetic fragment used in research as a more economical and accessible alternative for laboratory work. The two are sometimes referenced interchangeably in the literature, but strictly speaking TB-500 refers to the synthetic fragment and Tβ4 refers to the full endogenous protein.

How is TB-500 reconstituted for research use?

Bacteriostatic or sterile water is added to the lyophilized vial according to the volume protocol used in the specific research application. Reconstitution volume varies by intended working concentration. Investigators should reference established protocols for their experimental model rather than rely on a generic dilution.

Can TB-500 be combined with BPC-157 in research?

Combination research using TB-500 and BPC-157 is one of the more active sub-areas of recovery peptide work, on the rationale that the two compounds act through complementary rather than overlapping pathways. For the comparative research overview, including methodology considerations specific to multi-peptide protocols, see BPC-157 and TB-500 Research. For a single combination formulation containing both compounds plus GHK-Cu, see the GLOW-70mg research kit.

How is TB-500 quality verified?

Each batch is tested independently by third-party laboratories using reverse-phase HPLC for purity quantification and mass spectrometry for identity confirmation. The Certificate of Analysis is retrievable by batch number from the COA Lookup page. Genevium ships nothing below 99% HPLC purity.

For laboratory solution preparation, the reconstitution calculator determines the bacteriostatic water volume required to achieve a target concentration for a given quantity of lyophilized peptide.